Enlivex (ENLV) has released an update.
Enlivex Therapeutics announced a major milestone as the Japanese Patent Office granted a notice of allowance for a patent covering its Allocetra™ treatment for osteoarthritis, expected to be formally issued by mid-2025. This patent, extending protection through 2040, strengthens Enlivex’s intellectual property position and highlights its strategic focus on developing innovative therapies for unmet medical needs in key global markets.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
